CLDF Title
Contact Us | Bookmark
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Featured Programs
  Liver News - REUTERS   Congress Calendar   Physician Resources  
Novo Nordisk and Gilead team up to test fatty liver disease treatment
Clusters of autoimmune liver disease suggest environmental trigger
US liver cancer deaths more common with less education
Fecal microbiome signature detects cirrhosis in nonalcoholic fatty-liver disease
More heart, lung transplants possible with therapy to clear Hep C from donor organs
View Complete News Library
View all Congresses
  Featured Abstracts          
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs
Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
Vitamin D deficiency and health-related quality of life in chronic hepatitis C
Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience
Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence
Association of Intake of Whole Grains and Dietary Fiber With Risk of Hepatocellular Carcinoma in US Adults
Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease: prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study
Identifying and Treating Nonalcoholic Fatty Liver Disease
Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study
Correlation Between Adiponectin Gene rs1501299 Polymorphism and Nonalcoholic Fatty LiverDisease Susceptibility: A Systematic Review and Meta-Analysis
Health and Economic Burden of Nonalcoholic Fatty Liver Disease in the United States and Its Impact on Veterans
Mini-review: end-points for drug treatment in NASH
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Western Pacific Region, 2005-2017
Hepatitis B: Screening, Prevention, Diagnosis, and Treatment
Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center
Patterns and Predictors of Mortality after Waitlist Dropout of Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma
Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial
The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD
Evidence of bias during liver transplant evaluation of nonalcoholic steatohepatitis cirrhosis patients
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
Achieving Excellence in Hepatitis B Virus Care for Veterans in the Veterans Health Administration
Pelvic Floor Dysfunction in the Female Athlete
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
Bridging the access gap: Medicare ineligibility in people living with chronic hepatitis B
Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses
A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B
Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients
Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program
Treating HCV Infection: It Doesn't Get Much Better Than This
Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA
Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care
Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care
The successful scale-up of direct-acting antiviral hepatitis C treatments will benefit from concerted investments in implementation science
Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States
Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association with Outcomes: Single-Center Experience
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?
Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes
Weighing the benefits of hepatocellular carcinoma surveillance against potential harms
Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ?-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Regorafenib: a promising treatment for hepatocellular carcinoma
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multi-Center Study
The Psychomotor Vigilance Task: Role in the Diagnosis of Hepatic Encephalopathy and Relationship with Driving Ability
          View All Abstracts  
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.